DCOY Decoy Therapeutics Inc. stock chart & analysis
Conviction 49HealthcareScan · Tue, Nov 10, 2026Decoy Therapeutics Inc. (DCOY) closed at $1.10 (+0.00%) on Nov 10, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 37, -94.3% from its 52-week high, -89.5% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why DCOY moved
From the StockSetups movers recaps that covered DCOY, newest first. A recap states what was known that day.
- Premarket+45.6%
The catalyst appears to be a warrant inducement transaction, with Decoy issuing a correction to an earlier press release on September 22.
Premarket Movers Sept 23, 2026: BENF, WHLR, MSS → - Premarket+119.2%
Yahoo Finance reports this morning that Decoy Therapeutics is exploring a pan-filovirus program via the FDA Animal Rule pathway and pursuing non-dilutive funding.
Premarket Movers Sept 22, 2026: LHSW, DCOY, TOPS →
Financials as of Tue, Jun 30, 2026 · quarterly.
DCOY technical analysis
Trend
DCOY is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 41.9% below the 50-day ($1.89) and 79.5% below the 200-day ($5.37). ADX(14) at 7 points to a weak trend — more range than direction.
Momentum
RSI(14) is 37, in the bearish half of its range. The MACD histogram is positive.
Volume and volatility
Volume on the latest session ran 0.2× its 20-day average. It trades about $57,961 a day on average. ATR(14) is $0.1559, 14.2% of price — its typical daily range. Bollinger Bands are in a squeeze (2 sessions) — volatility is compressed. On-balance volume is trending down. Chaikin Money Flow (-0.14) shows distribution.
Key levels
The chart pattern's support is $0.9650 and its resistance $4.43. The 52-week range is $0.9000 to $19.22; price is 94.3% below the high and 22.2% above the low. The VWAP anchored at the 52-week high is $5.55, above price.
Performance
DCOY returned -0.9% (1 week), -23.1% (1 month), -69.4% (3 months), -78.6% (6 months), -89.5% (year to date).
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Pharmaceutical Preparations · Listed 2015 · 11 employees
Insider activity
SEC Form 4 transactions in DCOY
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Burleson Tess Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
Lieber Jonathan I Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
PIERCE FREDERICK II Chief Executive Officer · Common Stock · 2026-08-31 | Grant | 33.45K | — | 2026-08-31 | 2026-09-02 |
HANISH ARNOLD C Director · Common Stock · 2026-08-31 | Grant | 3K | — | 2026-08-31 | 2026-09-02 |
Rosenblum Mark J Chief Financial Officer · Common Stock · 2026-08-31 | Grant | 9.68K | — | 2026-08-31 | 2026-09-02 |
Lammers Paul Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
McVicar William K. Director · Common Stock · 2026-08-31 | Grant | 3K | — | 2026-08-31 | 2026-09-02 |
Hibner Barbara Louise Chief Scientific Officer · Common Stock · 2026-08-31 | Grant | 4.22K | — | 2026-08-31 | 2026-09-02 |
Marschel Peter Klaus Chief Business Officer · Common Stock · 2026-08-31 | Grant | 3.9K | — | 2026-08-31 | 2026-09-02 |
Gauthier Patricia G. Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
SEC filings
EDGAR filings in DCOY · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.